Exciting Virtual Event Announced by Lexeo Therapeutics
Lexeo Therapeutics, Inc. (NASDAQ: LXEO), a pioneering company in genetic medicine, is set to host an insightful virtual event designed for healthcare professionals and stakeholders. This event titled "A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy," will take place during the Global Cardiovascular Clinical Trialists (CVCT) Forum. The session aims to educate and engage attendees in an important discussion about managing specific cardiac conditions.
Key Expert Insights
The event will highlight a conversation featuring Dr. Victoria Parikh, an esteemed Associate Professor of Cardiovascular Medicine at Stanford University. Dr. Parikh, who leads the Stanford Center for Inherited Cardiovascular Disease, will share her expertise on the complexities surrounding PKP2-associated arrhythmogenic cardiomyopathy, a condition significantly affecting heart health.
Join the Engaging Discussion
For analysts and investors eager to learn more, there is an opportunity to participate in this crucial event. Attendees can register on Lexeo's dedicated News & Events page. Additionally, a replay of the event will be made available for those who cannot attend the live session, ensuring that valuable information is accessible to all interested parties.
About Lexeo Therapeutics
Based in New York City, Lexeo Therapeutics is committed to enhancing heart health by spearheading innovative genetic treatment solutions. The company is developing a portfolio of therapeutics targeting the genetic underpinnings of serious cardiac diseases. Among their advancements are candidates like LX2006, aimed at Friedreich ataxia, and LX2020, targeting PKP2 arrhythmogenic cardiomyopathy. Each of these efforts demonstrates Lexeo's commitment to addressing unmet medical needs in the cardiovascular field.
Connecting with Lexeo
For media inquiries, please reach out to Media@lexeotx.com. Investors can connect with Carlo Tanzi, Ph.D., via email at ctanzi@kendallir.com. Lexeo Therapeutics is enthusiastic about engaging with its community as it charts a path forward in the dynamic landscape of genetic medicine.
Frequently Asked Questions
What is the focus of the upcoming Lexeo event?
The event will focus on managing PKP2-associated arrhythmogenic cardiomyopathy, featuring expert insights from Dr. Victoria Parikh.
How can I attend the Lexeo Therapeutics event?
Interested parties can register for the event on Lexeo's News & Events page on their website.
Who is Dr. Victoria Parikh?
Dr. Victoria Parikh is an Associate Professor of Cardiovascular Medicine at Stanford University, specializing in inherited cardiovascular diseases.
What is Lexeo Therapeutics' mission?
Lexeo Therapeutics aims to transform heart health through innovative genetic medicine and addressing the genetic causes of cardiovascular diseases.
How can I contact Lexeo Therapeutics for media or investor inquiries?
Media inquiries can be directed to Media@lexeotx.com, while investors may contact Dr. Carlo Tanzi at ctanzi@kendallir.com.